blarcamesine
https://www.sciencedirect.com/science/article/pii/S2274580724006083
donanemab
https://jamanetwork.com/journals/jama/fullarticle/2807533
https://pubmed.ncbi.nlm.nih.gov/37459141/
lecanemab
https://www.nejm.org/doi/10.1056/NEJMoa2212948
https://pubmed.ncbi.nlm.nih.gov/36449413/

https://www.anavex.com/investor-material
https://www.anavex.com/post/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-iii-data-in
https://www.anavex.com/post/new-phase-iib-iii-clinical-data-demonstrates-over-three-years-of-continuous-treatment-with-oral-blar
https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-fourth-quarter-financial-results-and-provides-business-upda
https://www.anavex.com/_files/ugd/79bcf7_da38b4e0ad4b4ff888363403e3962ef2.pdf
https://clinicaltrials.gov/study/NCT04314934?term=NCT04314934&intr=NCT04314934&rank=1
https://clinicaltrials.gov/study/NCT03887455
https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/evaluation-medicines-step-step#further-consultations-by-day-210-13156
https://investor.lilly.com/news-releases/news-release-details/results-lillys-landmark-phase-3-trial-donanemab-presented
https://seekingalpha.com/article/4748984-playing-the-odds-of-anavex-alzheimers-drug-approval
https://www.youtube.com/watch?v=IYUoANr3cMo
https://www.anavex.com/_files/ugd/79bcf7_da38b4e0ad4b4ff888363403e3962ef2.pdf
https://www.alz.org/getmedia/76e51bb6-c003-4d84-8019-e0779d8c4e8d/alzheimers-facts-and-figures.pdf
https://pmc.ncbi.nlm.nih.gov/articles/PMC11095490/
https://pubmed.ncbi.nlm.nih.gov/29233480/
https://pmc.ncbi.nlm.nih.gov/articles/PMC5803316/
file://AVXL-%20Jones%20Research-%20nov%2026%202024.pdf
https://jonestrading.bluematrix.com/links2/pdf/53e831af-8e5a-45df-8897-c32b3cf072e4
https://www.alz.org/alzheimers-dementia/facts-figures?utm_source=google&utm_medium=paidsearch&utm_campaign=google_grants&utm_content=alzheimers&gad_source=1
https://pmc.ncbi.nlm.nih.gov/articles/PMC9013315/#:~:text=The%202020%20US%20census%20adjusted%20prevalence%20of%20all%2Dcause%20MCI,than%20Whites%20(32.0%25%20vs.
https://www.bumc.bu.edu/camed/2021/01/13/approximately-half-of-ad-dementia-cases-are-mild-one-fifth-are-severe/#:~:text=BUSM%20researchers%20have%20found%20that,19.3%20percent%20are%20severe%20cases.
https://www.anavex.com/investor-material
https://www.anavex.com/news-events-updates
https://www.anavex.com/post/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-iii-data-in
https://www.sciencedirect.com/science/article/pii/S2274580724006083
https://www.anavex.com/post/new-phase-iib-iii-clinical-data-demonstrates-over-three-years-of-continuous-treatment-with-oral-blar
https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-fourth-quarter-financial-results-and-provides-business-upda
https://wsw.com/webcast/cowen177/avxl/2042841
https://www.anavex.com/post/anavex-2-73-blarcamesine-shows-clinical-benefit-in-long-term-48week-phase-2-extension-study-in-pdd
https://www.anavex.com/press-releases/anavex-life-sciences-announces-positive-results-from-proof-of-concept-controlled-phase-2-clinical-trial-evaluating-anavex%C2%AE2-73-(blarcamesine)-in-parkinson%E2%80%99s-disease-dementia
https://pmc.ncbi.nlm.nih.gov/articles/PMC10483037/#:~:text=Introduction,50%20and%20above%20%5B4%5D.
https://www.bumc.bu.edu/camed/2021/01/13/approximately-half-of-ad-dementia-cases-are-mild-one-fifth-are-severe/#:~:text=BUSM%20researchers%20have%20found%20that,19.3%20percent%20are%20severe%20cases
https://pmc.ncbi.nlm.nih.gov/articles/PMC9013315/#:~:text=The%202020%20US%20census%20adjusted%20prevalence%20of%20all%2Dcause%20MCI,than%20Whites%20(32.0%25%20vs
https://www.anavex.com/_files/ugd/79bcf7_da38b4e0ad4b4ff888363403e3962ef2.pdf
https://en.wikipedia.org/wiki/Donepezil#:~:text=Donepezil%20was%20approved%20for%20medical,more%20than%203%20million%20prescriptions.
https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U.S.-FDA-Approval-for-MemantineDonepezil-Extended-Release-Capsules-and-Everolimus-Tablets-for-Oral-Suspension-and-Tentative-U.S.-FDA-Approval-for-Rifaximin/default.aspx
https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi
https://www.eisai.com/news/2025/news202515.html#:~:text=%E2%80%9CThe%20TGA%20proposed%20a%20narrow,slow%20the%20progression%20of%20AD.
https://www.alz.org/alzheimers-dementia/facts-figures
https://nature.com/articles/s43856-024-00527-6#:~:text=Alzheimer's%20disease%20medications&text=Approximately%20half%20of%20the%20patients,Donepezil%20and%20Memantine%20with%209.11%25.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5975499/#:~:text=Firstly%2C%20the%20patents%20expired%20on,and%20rivastigmine%20in%20July%202012.
https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U.S.-FDA-Approval-for-MemantineDonepezil-Extended-Release-Capsules-and-Everolimus-Tablets-for-Oral-Suspension-and-Tentative-U.S.-FDA-Approval-for-Rifaximin/default.aspx
https://www.anavex.com/post/anavex-life-sciences-provides-update-rett-syndrome-program
https://investors.biogen.com/static-files/c47a6017-f24a-4f02-ae64-dadcc1ec104e
https://investors.biogen.com/static-files/4c2f5ac9-7058-4b6f-81ef-11a2125c6698
https://investors.biogen.com/static-files/75f1044b-a254-48e9-acdb-bcb0263930b0
https://investors.biogen.com/static-files/a4eadd7a-6e77-4110-8289-94816df02324




